JTL's Principal Activity is the development and provision of healthcare industry service technologies and the development of integrated dispensing automation systems for the pharmaceutical and healthcare sectors.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||-|
|vs ASX 200 (1yr)||-75.89%|
Jayex Technology Limited (JTL, formerly Jayex Healthcare Limited) is a provider in the United Kingdom and Australia of integrated healthcare services delivery platforms, incorporating the Company's five interconnected and proprietary technologies. The products/services are: Enlighten patient workflow platform; Appointuit patient engagement solution; Pharmacy Delivery 2 U prescription delivery service; BluePoint remote pharmacy prescription processing and dispensing terminal; and the Jayex Connect - the complete cloud-based Patient Engagement Platform.
No incorporation details available.
DPS and Yield calculations use the Pay Date.
|Mr Nicholas Harper||Non-Executive Director||Sep 2020||
Mr Nicholas Harper
Mr Harper has over thirty years' experience working in software development. During that time, he has worked in the public sector (local government), investment banking and the aviation sector in a wide variety of roles and with varied responsibilities. Nick has worked on implementing and maintaining many different types of software systems from batch valuation systems to real-time data processing. Based in the UK, He also has experience of project management and software team building.
|Mr Michael Denis Boyd||Executive Chairman,Executive Director||May 2017||
Mr Michael Denis Boyd
Executive Chairman,Executive Director
Mr Boyd is the Chairman of the Company and has been involved since its inception in 2004. Based in Melbourne, he has led the corporate structuring of the Company and the development of the Group's strategic vision. On a practical level he has initiated contacts with all stakeholder groups including professional bodies, regulatory boards, wholesale distributors and pharmacy groups and individuals. Mr. Boyd has been involved in the creation of new enterprises, both in the private and public sectors, for over 27 years. Mr. Boyd has been successful in developing and growing new projects in diverse areas including healthcare, telecommunications and finance. Trained as a Chartered Accountant, he was a founding Director and Chairman of Sonic Healthcare Ltd, now an ASX listed top 50 company. After leaving Sonic he started Foundation Healthcare, growing it to over 800 healthcare professionals before it was acquired by Sonic. He was also a founding partner of Iridium Satellite bringing it out from bankruptcy to now a NASDAQ listed company.
|Mr Michael Chan||Non-Executive Director||Mar 2017||
Mr Michael Chan
Mr Chan has experience in broad based financial services for the past 30 years with hands on knowledge in both consumer and commercial sectors of the business. Michael is the founder and Managing Director at AMG Corporate Pty Ltd, a holder of an Australian Credit Licence which is primarily a debt advisory business. Prior to establishing AMG, Michael worked in key roles involved with strategic business development and marketing at several companies, both in the private and public sectors. Mr Chan has had a past affiliation with Make a Wish Foundation and more recently is the founder and chairman of The Mate Foundation - a men's health initiative with its principal purpose to help raise awareness of men's health diseases, which is due to launch shortly. He has over the years also undertaken philanthropic work for various other charities and causes in his community.
|Ms Melanie Jaye Leydin||Company Secretary||Aug 2015|
|Mr Brian Renwick||Non-Executive Director||Jul 2009||
Mr Brian Renwick
Mr. Renwick is experienced across the pharmaceutical and healthcare sector in Australia. His involvement with sector commenced in finance roles that led into commercial analysis, marketing and sales. From this broad commercial experience in the manufacturing end of the supply chain he moved into the wholesaling with various business development roles in retail and hospital pharmacy. Mr Renwick's roles broadened into commercial and business development including as general manager for a corporate pharmacy business. He has completed two Business Development roles within the CSL Limited group. With his detailed commercial knowledge and broad experience across the healthcare sector, Brian has provided consulting advice to Jayex since 2006 and is an important member of the team.
|Nathan Woodard||Chief Financial Officer||N/A|
JTL directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|22/09/21||Michael Chan||Issued||624,545||$0.025||$15,613||Rights issue|
|22/09/21||Michael Boyd||Issued||26,970,970||$0.025||$674,274||Rights issue|
|22/09/21||Brian Renwick||Issued||415,218||$0.025||$10,380||Rights issue|
|30/06/21||Michael Chan||Buy||+20,000||$0.027||$539||On-market trade|
The current holdings of JTL directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Vector London Ltd||28/03/2022||19,003,378||7.62|
|Covenant Holdings (WA) Pty Ltd||28/03/2022||103,883,880||41.68|
12 month transaction history compiled from ASX announcements.
|Date||Name||Bought||Previous %||New %|
|22-09-21||Michael Boyd and Covenant Holdings (WA) Pty Ltd||26,970,970||36.70||43.29|
|04-06-21||Michael Boyd and Covenant Holdings (WA) Pty Ltd||1,714,831||45.77||41.93|
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.